Peter A Merkel

List of Publications by Year
in descending order

312 papers	30,308 citations	6613 79 h-index	5539 163 g-index
327 all docs	327 docs citations	327 times ranked	19192 citing authors

#	Article	IF	Citations
1	Core Set of Domains for Outcome Measures in BehÃ§et's Syndrome. Arthritis Care and Research, 2022, 74, 691-699.	3.4	21
2	Reply. Arthritis and Rheumatology, 2022, 74, 545-546.	5.6	0
3	Hypothyroidism in vasculitis. Rheumatology, 2022, 61, 2942-2950.	1.9	2
4	Serum Biomarkers of Disease Activity in Longitudinal Assessment of Patients with <scp>ANCAâ€Associated</scp> Vasculitis. ACR Open Rheumatology, 2022, 4, 168-176.	2.1	6
5	Patient Perceptions and Preferences Regarding Telemedicine for Autoimmune Rheumatic Diseases Care During the <scp>COVID</scp>â€19 Pandemic. Arthritis Care and Research, 2022, 74, 1049-1057.	3.4	10
6	Use of 18F-fluorodeoxyglucose positron emission tomography to standardize clinical trial recruitment in Takayasuâ€™s arteritis. Rheumatology, 2022, 61, 4047-4055.	1.9	10
7	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis. Arthritis and Rheumatology, 2022, 74, 386-392.	5.6	50
8	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. Annals of the Rheumatic Diseases, 2022, 81, 309-314.	0.9	157
9	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis. Arthritis and Rheumatology, 2022, 74, 393-399.	5.6	71
10	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Annals of the Rheumatic Diseases, 2022, 81, 321-326.	0.9	112
11	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis. Arthritis and Rheumatology, 2022, 74, 400-406.	5.6	62
12	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Annals of the Rheumatic Diseases, 2022, 81, 315-320.	0.9	145
13	Medication Interruptions and Subsequent Disease Flares During the <scp>COVID</scp>â€19 Pandemic: A Longitudinal Online Study of Patients With Rheumatic Disease. Arthritis Care and Research, 2022, 74, 733-740.	3.4	16
14	Comparative efficacy and safety of alternative glucocorticoids regimens in patients with ANCA-associated vasculitis: a systematic review. BMJ Open, 2022, 12, e050507.	1.9	11
15	The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis. BMJ, The, 2022, 376, e064604.	6.0	42
16	Psychometric properties of outcome measurement instruments for ANCA-associated vasculitis: a systematic literature review. Rheumatology, 2022, 61, 4603-4618.	1.9	7
17	Response to: Correspondence on â€ 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitisâ€™ by Joanna C Robson et al and â€˜2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitisâ€™ by Ravi Suppiah et al. Annals of the Rheumatic Diseases, 2022, , annrheumdis-2022-222362.	0.9	12
18	Obinutuzumab as treatment for ANCA-associated vasculitis. Rheumatology, 2022, 61, 3814-3817.	1.9	11

#	Article	IF	Citations
19	The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over time. Seminars in Arthritis and Rheumatism, 2022, 55, 152010.	3.4	32
20	FC057: Incidence of Infections in the Avacopan Group Versus Prednisone Group in Anca-Associated Vasculitis, Results from the Phase 3 Advocate Study. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
21	An international Delphi exercise to identify items of importance for measuring response to treatment in ANCA-associated vasculitis. Seminars in Arthritis and Rheumatism, 2022, 55, 152021.	3.4	2
22	Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis. Interactive Journal of Medical Research, 2022, 11, e27273.	1.4	2
23	Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis. Arthritis Research and Therapy, 2022, 24, .	3.5	12
24	Targeted Program in an Academic Rheumatology Practice to Improve Compliance With Opioid Prescribing Guidelines for the Treatment of Chronic Pain. Arthritis Care and Research, 2021, 73, 1425-1429.	3.4	4
25	Sequenceâ€Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in ADA2. Arthritis and Rheumatology, 2021, 73, 512-519.	5.6	34
26	Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. Journal of Scleroderma and Related Disorders, 2021, 6, 66-76.	1.7	12
27	Concerns, Healthcare Use, and Treatment Interruptions in Patients With Common Autoimmune Rheumatic Diseases During the COVID-19 Pandemic. Journal of Rheumatology, 2021, 48, 603-607.	2.0	56
28	Clinical course of 602 patients with Takayasu's arteritis: comparison between Childhood-onset versus adult onset disease. Rheumatology, 2021, 60, 2246-2255.	1.9	44
29	Effects of the COVIDâ€19 Pandemic on Patients Living With Vasculitis. ACR Open Rheumatology, 2021, 3, 17-24.	2.1	10
30	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. American Journal of Human Genetics, 2021, 108, 84-99.	6.2	26
31	Response to: â€˜Correspondence on â€˜Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitisâ€™â€™ by Parikh et al. Annals of the Rheumatic Diseases, 2021, , annrheumdis-2020-219329.	0.9	1
32	Avacopan for the Treatment of ANCA-Associated Vasculitis. New England Journal of Medicine, 2021, 384, 599-609.	27.0	461
33	Multifocal neutrophilic meningoencephalitis: a novel disorder responsive to anakinra. Journal of Neurology, 2021, 268, 2995-2999.	3.6	1
34	Reply. Arthritis and Rheumatology, 2021, 73, 1089-1089.	5.6	0
35	Pulmonary involvement in primary systemic vasculitides. Rheumatology, 2021, 61, 319-330.	1.9	16
36	Patient-Powered Research Networks of the Autoimmune Research Collaborative: Rationale, Capacity, and Future Directions. Patient, 2021, 14, 699-710.	2.7	13

#	Article	IF	Citations
37	P158â€ƒPerformance of laser-derived imaging for assessing digital perfusion in clinical trials of systemic-related digital vasculopathy: a systematic literature review. Rheumatology, 2021, 60, .	1.9	0
38	Diagnostic delays in vasculitis and factors associated with time to diagnosis. Orphanet Journal of Rare Diseases, 2021, 16, 184.	2.7	20
39	Clinical Manifestations and Longâ€Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. ACR Open Rheumatology, 2021, 3, 404-412.	2.1	21
40	FC 032THE EFFECT OF AVACOPAN, A COMPLEMENT C5A RECEPTOR INHIBITOR, ON KIDNEY FUNCTION IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS WITH RENAL DISEASE. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
41	Social Distancing, Health Care Disruptions, Telemedicine Use, and Treatment Interruption During the COVIDâ€19 Pandemic in Patients With or Without Autoimmune Rheumatic Disease. ACR Open Rheumatology, 2021, 3, 381-389.	2.1	19
42	Developing a core set of outcome measure domains to study Raynaud's phenomenon and digital ulcers in systemic sclerosis: Report from OMERACT 2020. Seminars in Arthritis and Rheumatism, 2021, 51, 640-643.	3.4	8
43	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis Care and Research, 2021, 73, 1088-1105.	3.4	90
44	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2021, 73, 1366-1383.	5.6	249
45	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis and Rheumatology, 2021, 73, 1349-1365.	5.6	231
46	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. Arthritis and Rheumatology, 2021, 73, 1384-1393.	5.6	32
47	Dynamic Changes in the Nasal Microbiome Associated With Disease Activity in Patients With Granulomatosis WithÂPolyangiitis. Arthritis and Rheumatology, 2021, 73, 1703-1712.	5.6	14
48	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. Arthritis Care and Research, 2021, 73, 1061-1070.	3.4	15
49	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Care and Research, 2021, 73, 1071-1087.	3.4	61
50	Developing a composite outcome tool to measure response to treatment in ANCA-associated vasculitis: A mixed methods study from OMERACT 2020. Seminars in Arthritis and Rheumatism, 2021, 51, 1134-1138.	3.4	4
51	Eosinophils in Health and Disease: A State-of-the-Art Review. Mayo Clinic Proceedings, 2021, 96, 2694-2707.	3.0	103
52	Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis. JCI Insight, 2021, 6, .	5.0	7
53	Composite outcomes at OMERACT: Multi-outcome domains and composite outcome domains. Seminars in Arthritis and Rheumatism, 2021, 51, 1370-1377.	3.4	3
54	Efficacy of leflunomide in the treatment of vasculitis. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 114-118.	0.8	3

#	Article	IF	Citations
55	Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrology Dialysis Transplantation, 2020, 35, 283-291.	0.7	40
56	Effect of Treatment on Imaging, Clinical, and Serologic Assessments of Disease Activity in Large-vessel Vasculitis. Journal of Rheumatology, 2020, 47, 99-107.	2.0	48
57	Derivation of an angiographically based classification system in Takayasuâ€™s arteritis: an observational study from India and North America. Rheumatology, 2020, 59, 1118-1127.	1.9	33
58	Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis. Journal of Rheumatology, 2020, 47, 1001-1010.	2.0	20
59	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. Arthritis Care and Research, 2020, 72, 1615-1624.	3.4	77
60	Diagnostic Assessment Strategies and Disease Subsets in Giant Cell Arteritis: Data From an International Observational Cohort. Arthritis and Rheumatology, 2020, 72, 667-676.	5.6	33
61	Outcome Measures in Large Vessel Vasculitis: Relationship Between Patientâ€, Physicianâ€, Imagingâ€, and Laboratoryâ€Based Assessments. Arthritis Care and Research, 2020, 72, 1296-1304.	3.4	23
62	Assessment of skin disease in scleroderma: Practices and opinions of investigators studying scleroderma. Journal of Scleroderma and Related Disorders, 2020, 5, 167-171.	1.7	7
63	Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. ACR Open Rheumatology, 2020, 2, 662-671.	2.1	64
64	Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review. Seminars in Arthritis and Rheumatism, 2020, 50, 1314-1325.	3.4	17
65	ANCA-associated vasculitis. Nature Reviews Disease Primers, 2020, 6, 71.	30.5	443
66	Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis. Frontiers in Immunology, 2020, 11, 2053.	4.8	12
67	Protocol for a randomized multicenter study for isolated skin vasculitis (ARAMIS) comparing the efficacy of three drugs: azathioprine, colchicine, and dapsone. Trials, 2020, 21, 362.	1.6	14
68	Cutaneous Manifestations of Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2020, 72, 1741-1747.	5.6	31
69	Harnessing health plan enrollee data to boost membership in patient-powered research networks. BMC Health Services Research, 2020, 20, 462.	2.2	2
70	Longâ€Term Safety of Rituximab in Granulomatosis with Polyangiitis or Microscopic Polyangiitis. Arthritis Care and Research, 2020, 73, 1372-1378.	3.4	11
71	A novel approach to conducting clinical trials in the community setting: utilizing patient-driven platforms and social media to drive web-based patient recruitment. BMC Medical Research Methodology, 2020, 20, 58.	3.1	20
72	Performance of laser-derived imaging for assessing digital perfusion in clinical trials of systemic sclerosis-related digital vasculopathy: A systematic literature review. Seminars in Arthritis and Rheumatism, 2020, 50, 1114-1130.	3.4	11

#	Article	IF	Citations
73	Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. New England Journal of Medicine, 2020, 382, 622-631.	27.0	465
74	Clinical associations of renal involvement in ANCA-associated vasculitis. Autoimmunity Reviews, 2020, 19, 102495.	5.8	47
75	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatology, 2020, 59, 487-494.	1.9	56
76	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology, 2020, 59, e1-e23.	1.9	128
77	Comment on: Derivation of an angiographically based classification system in Takayasuâ€™s arteritis: reply. Rheumatology, 2020, 59, 1184-1185.	1.9	1
78	Pulmonary Eosinophilic Granulomatosis with Polyangiitis Has IgG4 Plasma Cells and Immunoregulatory Features. American Journal of Pathology, 2020, 190, 1438-1448.	3.8	7
79	Patterns of clinical presentation in Takayasu's arteritis. Seminars in Arthritis and Rheumatism, 2020, 50, 576-581.	3.4	25
80	Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis. JCI Insight, 2020, 5, .	5.0	6
81	Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial. JMIR Research Protocols, 2020, 9, e16664.	1.0	50
82	Clinical Characteristics of an Internet-Based Cohort of Patient-Reported Diagnosis of Granulomatosis With Polyangiitis and Microscopic Polyangiitis: Observational Study. Journal of Medical Internet Research, 2020, 22, e17231.	4.3	13
83	Identifying Clinical Risk Factors for Opioid Use Disorder using a Distributed Algorithm to Combine Real-World Data from a Large Clinical Data Research Network. AMIA ... Annual Symposium proceedings, 2020, 2020, 1220-1229.	0.2	1
84	Early development of new cardiovascular risk factors in the systemic vasculitides. Clinical and Experimental Rheumatology, 2020, 38 Suppl 124, 126-134.	0.8	2
85	An interim report of the Scleroderma Clinical Trials Consortium working groups. Journal of Scleroderma and Related Disorders, 2019, 4, 17-27.	1.7	13
86	Arterial lesions in giant cell arteritis: A longitudinal study. Seminars in Arthritis and Rheumatism, 2019, 48, 707-713.	3.4	43
87	The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. Journal of Autoimmunity, 2019, 105, 102302.	6.5	24
88	Patient involvement in medical research: what patients and physicians learn from each other. Orphanet Journal of Rare Diseases, 2019, 14, 21.	2.7	29
89	Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis: A Randomized Controlled Study. Arthritis and Rheumatology, 2019, 71, 952-963.	5.6	82
90	Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. Journal of Allergy and Clinical Immunology, 2019, 143, 2170-2177.	2.9	82

#	Article	IF	Citations
91	MultiPLIER: A Transfer Learning Framework for Transcriptomics Reveals Systemic Features of Rare Disease. Cell Systems, 2019, 8, 380-394.e4.	6.2	92
92	Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis. Rheumatology, 2019, 58, 2203-2211.	1.9	37
93	Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis. Arthritis and Rheumatology, 2019, 71, 1888-1893.	5.6	25
94	Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis. Arthritis and Rheumatology, 2019, 71, 1879-1887.	5.6	23
95	Data linkages between patient-powered research networks and health plans: a foundation for collaborative research. Journal of the American Medical Informatics Association: JAMIA, 2019, 26, 594-602.	4.4	14
96	Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018. Journal of Rheumatology, 2019, 46, 1198-1201.	2.0	24
97	Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes . Patient Related Outcome Measures, 2019, Volume 10, 37-42.	1.2	9
98	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. Journal of Rheumatology, 2019, 46, 928-934.	2.0	6
99	Peripheral neuropathy in antineutrophil cytoplasmic antibody-associated vasculitides. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	6.0	34
100	Ascending Aortic Aneurysm Secondary to Isolated Noninfectious Ascending Aortitis. Journal of Clinical Rheumatology, 2019, 25, 186-194.	0.9	4
101	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. Arthritis and Rheumatology, 2019, 71, 964-971.	5.6	41
102	Updating OMERACT Core Set of Domains for ANCA-associated Vasculitis: Patient Perspective Using the International Classification of Function, Disability, and Health. Journal of Rheumatology, 2019, 46, 1415-1420.	2.0	7
103	Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 40-44.	0.8	7
104	Patients' experiences with BehÃ§et's syndrome: structured interviews among patients with different types of organ involvement. Clinical and Experimental Rheumatology, 2019, 37 Suppl 121, 28-34.	0.8	4
105	Evaluation of damage in giant cell arteritis. Rheumatology, 2018, 57, 322-328.	1.9	28
106	Comparison of magnetic resonance angiography and¹⁸F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis. Annals of the Rheumatic Diseases, 2018, 77, 1165-1171.	0.9	101
107	Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis. Arthritis and Rheumatology, 2018, 70, 1114-1121.	5.6	49
108	Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. Rheumatology, 2018, 57, 639-650.	1.9	20

#	Article	IF	Citations
109	Cross-phenotype analysis of Immunochip data identifies KDM4C as a relevant locus for the development of systemic vasculitis. Annals of the Rheumatic Diseases, 2018, 77, 589-595.	0.9	27
110	The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 251-257.	4.5	50
111	Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212713.	0.9	38
112	¹⁸Fâ€Fluorodeoxyglucoseâ€"Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis. Arthritis and Rheumatology, 2018, 70, 439-449.	5.6	241
113	Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatology International, 2018, 38, 675-682.	3.0	40
114	Nomenclature of Cutaneous Vasculitis. Arthritis and Rheumatology, 2018, 70, 171-184.	5.6	200
115	Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis. Steroids, 2018, 140, 159-166.	1.8	24
116	Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis. PLoS ONE, 2018, 13, e0205768.	2.5	6
117	Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure. Patient Related Outcome Measures, 2018, Volume 9, 17-34.	1.2	24
118	Role of Macrophage Migration Inhibitory Factor in Granulomatosis With Polyangiitis. Arthritis and Rheumatology, 2018, 70, 2077-2086.	5.6	12
119	Characterisation of the nasal microbiota in granulomatosis with polyangiitis. Annals of the Rheumatic Diseases, 2018, 77, 1448-1453.	0.9	37
120	Metabolic pathways and immunometabolism in rare kidney diseases. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212935.	0.9	101
121	Impact of vasculitis on employment and income. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 58-64.	0.8	4
122	Health-related outcomes of importance to patients with Takayasu's arteritis. Clinical and Experimental Rheumatology, 2018, 36 Suppl 111, 51-57.	0.8	6
123	The association of vascular risk factors with visual loss in giant cell arteritis. Rheumatology, 2017, 56, kew397.	1.9	16
124	A Randomized, Doubleâ€Blind Trial of Abatacept (CTLAâ€4Ig) for the Treatment of Takayasu Arteritis. Arthritis and Rheumatology, 2017, 69, 846-853.	5.6	131
125	A Randomized, Doubleâ€Blind Trial of Abatacept (CTLAâ€4Ig) for the Treatment of Giant Cell Arteritis. Arthritis and Rheumatology, 2017, 69, 837-845.	5.6	271
126	Infections and the risk of incident giant cell arteritis: a population-based, case-control study. Annals of the Rheumatic Diseases, 2017, 76, 1031-1035.	0.9	51

#	Article	IF	Citations
127	Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy. Scientific Reports, 2017, 7, 43953.	3.3	52
128	Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. Trials, 2017, 18, 112.	1.6	65
129	Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. New England Journal of Medicine, 2017, 376, 1921-1932.	27.0	682
130	Developing a Core Set of Outcome Measures for BehÃ§et Disease: Report from OMERACT 2016. Journal of Rheumatology, 2017, 44, 1750-1753.	2.0	25
131	Reply. Arthritis and Rheumatology, 2017, 69, 1505-1506.	5.6	0
132	Are the 1990 American College of Rheumatology vasculitis classification criteria still valid?. Rheumatology, 2017, 56, 1154-1161.	1.9	89
133	Temporal Trends of Venous Thromboembolism Risk Before and After Diagnosis of Giant Cell Arteritis. Arthritis and Rheumatology, 2017, 69, 176-184.	5.6	22
134	Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibodyâ€"Associated Vasculitis. Arthritis and Rheumatology, 2017, 69, 1054-1066.	5.6	130
135	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. American Journal of Human Genetics, 2017, 100, 64-74.	6.2	78
136	Composition corporelle, fonction pulmonaire et perte progressive de masse osseuse chez lâ€™adulte souffrant de mucoviscidose. Revue Du Rhumatisme (Edition Francaise), 2017, 84, 51-56.	0.0	0
137	Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. American Journal of Nephrology, 2017, 46, 231-238.	3.1	15
138	Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016. Journal of Rheumatology, 2017, 44, 1933-1937.	2.0	33
139	Assessment of Disease Activity in Large-vessel Vasculitis: Results of an International Delphi Exercise. Journal of Rheumatology, 2017, 44, 1928-1932.	2.0	22
140	The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica. Journal of Rheumatology, 2017, 44, 1515-1521.	2.0	33
141	Patient-reported outcomes in Takayasu's arteritis. Presse Medicale, 2017, 46, e225-e227.	1.9	4
142	Severe Infection in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. Journal of Rheumatology, 2017, 44, 1468-1475.	2.0	47
143	Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibodyâ€"associated vasculitis. Rheumatology, 2017, 56, 1962-1969.	1.9	48
144	Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. RMD Open, 2017, 3, e000449.	3.8	23

#	Article	IF	Citations
145	Rate of Comorbidities in Giant Cell Arteritis: A Population-based Study. Journal of Rheumatology, 2017, 44, 84-90.	2.0	43
146	Variation in the Treatment of Children Hospitalized With Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis in the US. Arthritis Care and Research, 2017, 69, 1377-1383.	3.4	15
147	The Pharmacogenomic Association of FcÎ³ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis. Arthritis and Rheumatology, 2017, 69, 169-175.	5.6	21
148	Patient-Reported Outcomes in Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 140-148.	4.5	24
149	Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis. Arthritis Care and Research, 2017, 69, 1004-1010.	3.4	11
150	Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3â€"Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis. Arthritis and Rheumatology, 2017, 69, 185-193.	5.6	45
151	Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis. Journal of Scleroderma and Related Disorders, 2017, 2, 11-18.	1.7	321
152	Experience With Direct-to-Patient Recruitment for Enrollment Into a Clinical Trial in a Rare Disease: A Web-Based Study. Journal of Medical Internet Research, 2017, 19, e50.	4.3	24
153	OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibodyâ€"associated Vasculitis. Journal of Rheumatology, 2017, 44, 1529-1535.	2.0	25
154	Clinical course and outcomes of childhood-onset granulomatosis with polyangiitis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 202-208.	0.8	5
155	IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 98-101.	0.8	3
156	The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. Orphanet Journal of Rare Diseases, 2016, 11, 66.	2.7	62
157	Trends in Longâ€Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis With Renal Disease. Arthritis and Rheumatology, 2016, 68, 1711-1720.	5.6	97
158	Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis. Analytical Chemistry, 2016, 88, 6317-6325.	6.5	24
159	The Birmingham Vasculitis Activity Score as a Measure of Disease Activity in Patients with Giant Cell Arteritis. Journal of Rheumatology, 2016, 43, 1078-1084.	2.0	37
160	Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis. JAMA - Journal of the American Medical Association, 2016, 315, 1975.	7.4	95
161	Diffuse atrophic papules and plaques, intermittent abdominal pain, paresthesias, and cardiac abnormalities in a 55-year-old woman. Journal of the American Academy of Dermatology, 2016, 75, 1274-1277.	1.2	9
162	Myeloperoxidaseâ€"Antineutrophil Cytoplasmic Antibody (ANCA)â€"Positive and ANCAâ€Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets. Arthritis and Rheumatology, 2016, 68, 2945-2952.	5.6	75

#	Article	IF	Citations
163	Development and validation of caseâ€finding algorithms for the identification of patients with antiâ€neutrophil cytoplasmic antibodyâ€associated vasculitis in large healthcare administrative databases. Pharmacoepidemiology and Drug Safety, 2016, 25, 1368-1374.	1.9	29
164	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis Care and Research, 2016, 68, 167-178.	3.4	13
165	Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3. Arthritis and Rheumatology, 2016, 68, 1700-1710.	5.6	132
166	Visual Complications in Patients with Biopsy-proven Giant Cell Arteritis: A Population-based Study. Journal of Rheumatology, 2016, 43, 1559-1565.	2.0	59
167	Comorbidities in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis versus the General Population. Journal of Rheumatology, 2016, 43, 1553-1558.	2.0	38
168	Body composition, lung function, and prevalent and progressive bone deficits among adults with cystic fibrosis. Joint Bone Spine, 2016, 83, 207-211.	1.6	15
169	Using patient-reported outcomes and PROMIS in research and clinical applications: experiences from the PCORI pilot projects. Quality of Life Research, 2016, 25, 2109-2116.	3.1	51
170	A small n sequential multiple assignment randomized trial design for use in rare disease research. Contemporary Clinical Trials, 2016, 46, 48-51.	1.8	31
171	Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Annals of the Rheumatic Diseases, 2016, 75, 1166-1169.	0.9	196
172	Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. Seminars in Arthritis and Rheumatism, 2016, 45, 475-482.	3.4	109
173	Severe Small-Vessel Vasculitis Temporally Associated With Administration of Ustekinumab. Journal of Drugs in Dermatology, 2016, 15, 359-62.	0.8	5
174	Mapping of the Outcome Measures in Rheumatology Core Set for Antineutrophil Cytoplasmic Antibodyâ€Associated Vasculitis to the International Classification of Function, Disability and Health. Arthritis Care and Research, 2015, 67, 255-263.	3.4	9
175	Adverse Events in Connective Tissue Diseaseâ€"Associated Pulmonary Arterial Hypertension. Arthritis and Rheumatology, 2015, 67, 2457-2465.	5.6	12
176	Serum Biomarkers in Patients with Relapsing Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss). PLoS ONE, 2015, 10, e0121737.	2.5	35
177	Incidence and mortality rates of biopsy-proven giant cell arteritis in southern Sweden. Annals of the Rheumatic Diseases, 2015, 74, 993-997.	0.9	100
178	Reliability, validity and responsiveness to change of the Saint Georgeâ€™s Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis. Rheumatology, 2015, 54, 1369-1379.	1.9	21
179	Identification of Susceptibility Loci in IL6, RPS9/LILRB3, and an Intergenic Locus on Chromosome 21q22 in Takayasu Arteritis in a Genomeâ€Wide Association Study. Arthritis and Rheumatology, 2015, 67, 1361-1368.	5.6	79
180	Apremilast for BehÃ§etâ€™s Syndrome â€" A Phase 2, Placebo-Controlled Study. New England Journal of Medicine, 2015, 372, 1510-1518.	27.0	204

#	Article	IF	Citations
181	Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study. Journal of Rheumatology, 2015, 42, 1213-1217.	2.0	129
182	Neutrophilâ€Related Gene Expression and Lowâ€Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis. Arthritis and Rheumatology, 2015, 67, 1922-1932.	5.6	116
183	Eosinophilic granulomatosis with polyangiitis (Churgâ€"Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. European Journal of Internal Medicine, 2015, 26, 545-553.	2.2	371
184	Cardiac Involvement in Granulomatosis with Polyangiitis. Journal of Rheumatology, 2015, 42, 1209-1212.	2.0	87
185	Brief Report: Defining the Nasal Transcriptome in Granulomatosis With Polyangiitis (Wegener's). Arthritis and Rheumatology, 2015, 67, 2233-2239.	5.6	17
186	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. American Journal of Human Genetics, 2015, 96, 565-580.	6.2	144
187	Allosteric modulation of proteinase 3 activity by anti-neutrophil cytoplasmic antibodies in granulomatosis with polyangiitis. Journal of Autoimmunity, 2015, 59, 43-52.	6.5	6
188	Outcome measures for Takayasu's arteritis. Current Opinion in Rheumatology, 2015, 27, 32-37.	4.3	34
189	Current Status, Goals, and Research Agenda for Outcome Measures Development in BehÃ§et Syndrome: Report from OMERACT 2014. Journal of Rheumatology, 2015, 42, 2436-2441.	2.0	18
190	Trends in bone mineral density in young adults with cystic fibrosis over a 15 year period. Journal of Cystic Fibrosis, 2015, 14, 526-532.	0.7	36
191	Comparison of Treatment Response in Idiopathic and Connective Tissue Diseaseâ€"associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1111-1117.	5.6	67
192	Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibodyâ€"associated Vasculitis Using the OMERACT Process. Journal of Rheumatology, 2015, 42, 2204-2209.	2.0	22
193	Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12. Journal of Rheumatology, 2015, 42, 2465-2469.	2.0	33
194	Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement. Journal of the American Society of Nephrology: JASN, 2015, 26, 976-985.	6.1	137
195	Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. Rheumatology, 2015, 54, 1351-1359.	1.9	52
196	Peripheral CD5+ B Cells in Antineutrophil Cytoplasmic Antibodyâ€"Associated Vasculitis. Arthritis and Rheumatology, 2015, 67, 535-544.	5.6	25
197	The informational needs of patients with ANCA-associated vasculitis--development of an informational needs questionnaire. Rheumatology, 2014, 53, 1414-1421.	1.9	20
198	Causal Attributions about Disease Onset and Relapse in Patients with Systemic Vasculitis. Journal of Rheumatology, 2014, 41, 923-930.	2.0	15

#	Article	IF	Citations
199	P10. Review of the expert panel methodology in the diagnostic and classification criteria for vasculitis study: a pilot study. Rheumatology, 2014, 53, i15-i16.	1.9	1
200	Updating the OMERACT Filter: Core Areas as a Basis for Defining Core Outcome Sets. Journal of Rheumatology, 2014, 41, 994-999.	2.0	20
201	Brief Report: The Value of a Patient Global Assessment of Disease Activity in Granulomatosis With Polyangiitis (Wegener's). Arthritis and Rheumatology, 2014, 66, 428-432.	5.6	28
202	Current Status of Outcome Measure Development in Vasculitis. Journal of Rheumatology, 2014, 41, 593-598.	2.0	31
203	An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). Annals of the Rheumatic Diseases, 2014, 73, 1376-1379.	0.9	128
204	Outcome Measures Used in Clinical Trials for BehÃ§et Syndrome: A Systematic Review. Journal of Rheumatology, 2014, 41, 599-612.	2.0	54
205	Patient-powered research networks: building capacity for conducting patient-centered clinical outcomes research. Journal of the American Medical Informatics Association: JAMIA, 2014, 21, 583-586.	4.4	61
206	Alcohol-induced vasculitis: Case report and commentary. Journal of the American Academy of Dermatology, 2014, 70, e42-e43.	1.2	5
207	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. Journal of Clinical Epidemiology, 2014, 67, 706-714.	5.0	52
208	Risk for Cardiovascular Disease Early and Late After a Diagnosis of Giant-Cell Arteritis. Annals of Internal Medicine, 2014, 161, 230.	3.9	2
209	Risk for Cardiovascular Disease Early and Late After a Diagnosis of Giant-Cell Arteritis. Annals of Internal Medicine, 2014, 160, 73-80.	3.9	133
210	Correlates and Responsiveness to Change of Measures of Skin and Musculoskeletal Disease in Early Diffuse Systemic Sclerosis. Arthritis Care and Research, 2014, 66, 1731-1739.	3.4	26
211	Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis. New England Journal of Medicine, 2013, 369, 417-427.	27.0	611
212	ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS). Clinical and Experimental Nephrology, 2013, 17, 619-621.	1.6	158
213	Identification of Multiple Genetic Susceptibility Loci in Takayasu Arteritis. American Journal of Human Genetics, 2013, 93, 298-305.	6.2	143
214	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatism, 2013, 65, 2737-2747.	6.7	2,359
215	Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. Annals of the Rheumatic Diseases, 2013, 72, 1003-1010.	0.9	183
216	Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2013, 72, 1342-1350.	0.9	109

#	Article	IF	Citations
217	L50. The future of international clinical trials in vasculitis. Presse Medicale, 2013, 42, 637-641.	1.9	2
218	Pregnancy Outcomes Among Patients With Vasculitis. Arthritis Care and Research, 2013, 65, 1370-1374.	3.4	44
219	Association of Granulomatosis With Polyangiitis (Wegener's) With HLAâ€“DPB1*04 and SEMA6A Gene Variants: Evidence From Genomeâ€Wide Analysis. Arthritis and Rheumatism, 2013, 65, 2457-2468.	6.7	138
220	Clinical image: Spinal gout presenting as acute low back pain. Arthritis and Rheumatism, 2013, 65, n/a-n/a.	6.7	6
221	New Features of Disease After Diagnosis in 6 Forms of Systemic Vasculitis. Journal of Rheumatology, 2013, 40, 1905-1912.	2.0	40
222	Urinary Biomarkers in Relapsing Antineutrophil Cytoplasmic Antibody-associated Vasculitis. Journal of Rheumatology, 2013, 40, 674-683.	2.0	39
223	Readability and Suitability Assessment of Patient Education Materials in Rheumatic Diseases. Arthritis Care and Research, 2013, 65, 1702-1706.	3.4	46
224	Illness Perceptions and Fatigue in Systemic Vasculitis. Arthritis Care and Research, 2013, 65, 1835-1843.	3.4	51
225	Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. Annals of the Rheumatic Diseases, 2012, 71, 1329-1334.	0.9	218
226	Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis. Rheumatology, 2012, 51, 100-109.	1.9	285
227	Association of Vascular Physical Examination Findings and Arteriographic Lesions in Large Vessel Vasculitis. Journal of Rheumatology, 2012, 39, 303-309.	2.0	51
228	Patterns and predictors of change in outcome measures in clinical trials in scleroderma: An individual patient metaâ€analysis of 629 subjects with diffuse cutaneous systemic sclerosis. Arthritis and Rheumatism, 2012, 64, 3420-3429.	6.7	69
229	Metaâ€analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis. Arthritis and Rheumatism, 2012, 64, 3463-3471.	6.7	33
230	Circulating Angiopoietin-2 as a Biomarker in ANCA-Associated Vasculitis. PLoS ONE, 2012, 7, e30197.	2.5	16
231	Assessment of healthâ€related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). Arthritis Care and Research, 2012, 64, 273-279.	3.4	49
232	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. Arthritis Care and Research, 2012, 64, 351-357.	3.4	49
233	Defining disease activity and damage in patients with small-vessel vasculitis. Cleveland Clinic Journal of Medicine, 2012, 79, S11-S15.	1.3	9
234	Systemic vasculitis--is it time to reclassify?. Rheumatology, 2011, 50, 643-645.	1.9	41

#	Article	IF	Citations
235	Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosis. Annals of the Rheumatic Diseases, 2011, 70, 704-704.	0.9	106
236	Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases, 2011, 70, 32-38.	0.9	394
237	Relationship Between Markers of Platelet Activation and Inflammation with Disease Activity in Wegenerâ€™s Granulomatosis. Journal of Rheumatology, 2011, 38, 1048-1054.	2.0	45
238	Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. Annals of the Rheumatic Diseases, 2011, 70, 80-85.	0.9	47
239	Antineutrophil Cytoplasmic Antibodies, Autoimmune Neutropenia, and Vasculitis. Seminars in Arthritis and Rheumatism, 2011, 41, 424-433.	3.4	19
240	Plasma Exchange for Renal Vasculitis and Idiopathic Rapidly Progressive Glomerulonephritis: A Meta-analysis. American Journal of Kidney Diseases, 2011, 57, 566-574.	1.9	179
241	The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis. Journal of Rheumatology, 2011, 38, 1480-1486.	2.0	105
242	Development of Outcome Measures for Large-vessel Vasculitis for Use in Clinical Trials: Opportunities, Challenges, and Research Agenda. Journal of Rheumatology, 2011, 38, 1471-1479.	2.0	79
243	A woman with severe lupus nephritis and difficult to control diabetes mellitus. Arthritis Care and Research, 2011, 63, 623-629.	3.4	6
244	A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care and Research, 2011, 63, 588-596.	3.4	147
245	Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care and Research, 2011, 63, 1055-1061.	3.4	63
246	Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). Arthritis Care and Research, 2011, 63, 1777-1781.	3.4	60
247	Granulomatosis with Polyangiitis (Wegener's): An alternative name for Wegener's Granulomatosis. Arthritis and Rheumatism, 2011, 63, 863-864.	6.7	244
248	Solid malignancies among etanerceptâ€treated patients with granulomatosis with polyangiitis (Wegener's): Longâ€term followup of a multicenter longitudinal cohort. Arthritis and Rheumatism, 2011, 63, 2495-2503.	6.7	58
249	Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis and Rheumatism, 2011, 63, 3988-3997.	6.7	59
250	IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 20736-20741.	7.1	74
251	Granulomatosis with Polyangiitis (Wegener's). Journal of the American Society of Nephrology: JASN, 2011, 22, 587-588.	6.1	49
252	Assessment of disease activity and progression in Takayasu's arteritis. Clinical and Experimental Rheumatology, 2011, 29, S86-91.	0.8	56

#	Article	IF	Citations
253	Genetics of vasculitis. Current Opinion in Rheumatology, 2010, 22, 157-163.	4.3	45
254	Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibodyâ€“associated vasculitis: A metaâ€analysis. Arthritis Care and Research, 2010, 62, 1166-1173.	3.4	200
255	Skin ulcers in a patient with SjÃ¶gren's syndrome. Arthritis Care and Research, 2010, 62, 1040-1046.	3.4	5
256	Patientâ€reported outcome assessment in vasculitis may provide important data and a unique perspective. Arthritis Care and Research, 2010, 62, 1639-1645.	3.4	86
257	Alpha₁â€antitrypsin deficiencyâ€“related alleles Z and S and the risk of Wegener's granulomatosis. Arthritis and Rheumatism, 2010, 62, 3760-3767.	6.7	87
258	Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. New England Journal of Medicine, 2010, 363, 221-232.	27.0	2,275
259	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Annals of the Rheumatic Diseases, 2010, 69, 1744-1750.	0.9	139
260	Measures of Response in Clinical Trials of Systemic Sclerosis: The Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS). Journal of Rheumatology, 2009, 36, 2356-2361.	2.0	43
261	Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9. Journal of Rheumatology, 2009, 36, 2362-2368.	2.0	35
262	Noninfectious Ascending Aortitis: Staying Ahead of the Curve. Journal of Rheumatology, 2009, 36, 2137-2140.	2.0	17
263	Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: A randomized, doubleâ€blind, placeboâ€controlled trial. Arthritis and Rheumatism, 2009, 60, 1102-1111.	6.7	137
264	Clinical research for rare disease: Opportunities, challenges, and solutions. Molecular Genetics and Metabolism, 2009, 96, 20-26.	1.1	320
265	Thromboembolic disease in vasculitis. Current Opinion in Rheumatology, 2009, 21, 41-46.	4.3	73
266	Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I. Arthritis and Rheumatism, 2008, 58, 15-25.	6.7	1,918
267	Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis. Arthritis and Rheumatism, 2008, 59, 746-753.	6.7	47
268	Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. Arthritis and Rheumatism, 2008, 59, 699-705.	6.7	109
269	Case 31-2008. New England Journal of Medicine, 2008, 359, 1603-1614.	27.0	7
270	EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Annals of the Rheumatic Diseases, 2007, 66, 605-617.	0.9	524

#	Article	IF	Citations
271	Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis. Annals of Internal Medicine, 2007, 146, 621.	3.9	491
272	Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis. Annals of Internal Medicine, 2007, 147, 611.	3.9	234
273	Recombinant human antiâ€"transforming growth factor Î²1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis and Rheumatism, 2007, 56, 323-333.	6.7	415
274	Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data metaâ€analysis. Arthritis and Rheumatism, 2007, 56, 2789-2797.	6.7	521
275	Nutrient Status of Adults with Cystic Fibrosis. Journal of the American Dietetic Association, 2007, 107, 2114-2119.	1.1	34
276	Outcome measures in systemic sclerosis: An update on instruments and current research. Current Rheumatology Reports, 2007, 9, 151-157.	4.7	57
277	Outcome measurements in scleroderma: results from a delphi exercise. Journal of Rheumatology, 2007, 34, 501-9.	2.0	45
278	Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestations. Journal of Rheumatology, 2007, 34, 1027-31.	2.0	22
279	Systemic sclerosis - continuing progress in developing clinical measures of response. Journal of Rheumatology, 2007, 34, 1194-200.	2.0	64
280	The future of damage assessment in vasculitis. Journal of Rheumatology, 2007, 34, 1357-71.	2.0	33
281	The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. Journal of Rheumatology, 2007, 34, 2446-50.	2.0	35
282	Brief Communication: High Incidence of Venous Thrombotic Events among Patients with Wegener Granulomatosis: The Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Annals of Internal Medicine, 2005, 142, 620.	3.9	277
283	A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis. Arthritis and Rheumatism, 2005, 52, 902-910.	6.7	43
284	Damage caused by Wegener's granulomatosis and its treatment: Prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis and Rheumatism, 2005, 52, 2168-2178.	6.7	171
285	Guide to Bone Health and Disease in Cystic Fibrosis. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1888-1896.	3.6	388
286	Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. Journal of Rheumatology, 2005, 32, 832-40.	2.0	107
287	Scleroderma--developing measures of response. Journal of Rheumatology, 2005, 32, 2477-80.	2.0	15
288	Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. Journal of Rheumatology, 2005, 32, 2488-95.	2.0	32

#	Article	IF	Citations
289	Hearing Loss in WegenerÊ¼s Granulomatosis. Otology and Neurotology, 2004, 25, 833-837.	1.3	50
290	Diagnostic imaging in Takayasu arteritis. Current Opinion in Rheumatology, 2004, 16, 31-37.	4.3	207
291	Domains of health-related quality of life important to patients with giant cell arteritis. Arthritis and Rheumatism, 2003, 49, 819-825.	6.7	35
292	Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. Journal of Rheumatology, 2003, 30, 1630-47.	2.0	104
293	Evaluation and treatment of vasculitis in the critically ill patient. Critical Care Clinics, 2002, 18, 321-344.	2.6	9
294	A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis and Rheumatism, 2002, 46, 1309-1318.	6.7	480
295	Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis and Rheumatism, 2002, 46, 2410-2420.	6.7	272
296	A disease-specific activity index for Wegener's granulomatosis: Modification of the Birmingham Vasculitis Activity Score. Arthritis and Rheumatism, 2001, 44, 912-920.	6.7	400
297	Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. Arthritis and Rheumatism, 2000, 43, 226-231.	6.7	165
298	Drug-associated antineutrophil cytoplasmic antibodyâ€"positive vasculitis: Prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis and Rheumatism, 2000, 43, 405.	6.7	390
299	Evaluation of antineutrophil cytoplasmic antibody seroconversion induced by minocycline, sulfasalazine, or penicillamine. Arthritis and Rheumatism, 2000, 43, 2488-2492.	6.7	48
300	Alternating antineutrophil cytoplasmic antibody specificity: Drug-induced vasculitis in a patient with Wegener's granulomatosis. Arthritis and Rheumatism, 1999, 42, 384-388.	6.7	43
301	Rheumatic disease and cystic fibrosis. Arthritis and Rheumatism, 1999, 42, 1563-1571.	6.7	34
302	Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: A multicenter, placebo-controlled, double-blind study. Arthritis and Rheumatism, 1998, 41, 670-677.	6.7	175
303	Drugs associated with vasculitis. Current Opinion in Rheumatology, 1998, 10, 45-50.	4.3	81
304	Measurement of functional status, self-assessment, and psychological well-being in scleroderma. Current Opinion in Rheumatology, 1998, 10, 589-594.	4.3	24
305	Prevalence of Antineutrophil Cytoplasmic Antibodies in a Large Inception Cohort of Patients with Connective Tissue Disease. Annals of Internal Medicine, 1997, 126, 866.	3.9	176
306	Heterotopic ossification in the setting of neuromuscular blockade. Arthritis and Rheumatism, 1997, 40, 1619-1627.	6.7	35

#	Article	IF	Citations
307	The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. American Journal of Medicine, 1996, 101, 576-583.	1.5	158
308	Cocaine-associated cerebral vasculitis. Seminars in Arthritis and Rheumatism, 1995, 25, 172-183.	3.4	110
309	Evaluation of a simple office-based strategy for increasing influenza vaccine administration and the effect of differing reimbursement plans on the patient acceptance rate. Journal of General Internal Medicine, 1994, 9, 679-683.	2.6	35
310	Correction of Hyperinsulinemia by Glyburide Treatment in Nondiabetic Patients with Thalassemia Major. Pediatric Research, 1993, 33, 497-500.	2.3	13
311	Insulin Resistance and Hyperinsulinemia in Patients with Thalassemia Major Treated by Hypertransfusion. New England Journal of Medicine, 1988, 318, 809-814.	27.0	214
312	317.â€ƒRe-Appraisal of the 1990 American College of Rheumatology Classification Criteria for Systemic Vasculitis: Analysis of Data from the Diagnostic and Classification Criteria in Vasculitis Study. Rheumatology, 0, , .	1.9	0